Perifosine + Sunitinib Malate for Patients With Advanced Cancers
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This study is a Phase I trial in two parts. In part 1, a MTD to the combination of perifosine
and sunitinib malate will be determined. In part 2, with the MTD as a starting point, a group
of patients will be accrued with the goal of ensuring that they will be able to tolerate at
least two courses of therapy, which would make them evaluable for response in a Phase II
study.